EUVIMEDEUVIMED entdecken
Crossref

Molecular characterization of Chinese patients with small bowel adenocarcinoma

Bryan Jin, Bin Lv, Zhengqing Yan, Wenshuai Li, Huan Song, Haoshu Cui, Yao Liu, Bin Zhong, Xin Shen, Xiao Li, Bei Zhang, Shiqing Chen und 4 weitere

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03441-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Bryan Jin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Intestinal Neoplasms, Mutation, Circulating Tumor DNA. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Rising-Star Program, Clinical Research Plan of SHDC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract, and its unique location within the small intestine presents difficulties in obtaining tissue samples from the lesions. This limitation hinders the research and development of effective clinical treatment methods. Circulating tumor DNA (ctDNA) analysis holds promise as an alternative approach for investigating SBA and guiding treatment decisions, thereby improving the prognosis of SBA. METHODS: Between January 2017 and August 2021, a total of 336 tissue or plasma samples were obtained and the corresponding mutation status in tissue or blood was evaluated with NGS. RESULTS AND CONCLUSIONS: The study found that in SBA tissues, the most commonly alternated genes were TP53, KRAS, and APC, and the most frequently affected pathways were RTK-RAS-MAPK, TP53, and WNT. Notably, the RTK-RAS-MAPK pathway was identified as a potential biomarker that could be targeted for treatment. Then, we validated the gene mutation profiling of ctDNA extracted from SBA patients exhibited the same characteristics as tissue samples for the first time. Subsequently, we applied ctDNA analysis on a terminal-stage patient who had shown no response to previous chemotherapy. After detecting alterations in the RTK-RAS-MAPK pathway in the ctDNA, the patient was treated with MEK + EGFR inhibitors and achieved a tumor shrinkage rate of 76.33%. Our study utilized the largest Chinese SBA cohort to uncover the molecular characteristics of this disease, which might facilitate clinical decision making for SBA patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaIntestinal NeoplasmsMutationCirculating Tumor DNAHumansMaleFemaleMiddle AgedAgedBiomarkers, TumorIntestine, SmallAdultProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Adenomatous Polyposis Coli ProteinChinaPrognosisEast Asian People

Stichwörter der Autor:innen

Molecular characteristicsRTK–RAS–MAPKSmall bowel adenocarcinomaTrametinibctDNA

Substanzen

Circulating Tumor DNABiomarkers, TumorKRAS protein, humanAPC protein, humanProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Adenomatous Polyposis Coli ProteinTP53 protein, human

Autor:innen und Institutionen

  • Department of Digestive Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China.
  • The Medical Department, 3D Medicines Inc., Shanghai, 200120, China.
  • Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, 200120, China.
  • Department of Digestive Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China. calebzww@yeah.net.
  • Department of Digestive Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China. jieliu@fudan.edu.cn.
  • National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China. jieliu@fudan.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Rising-Star Program
  • Clinical Research Plan of SHDC

Zitieren

APA

Jin, B., Lv, B., Yan, Z., Li, W., Song, H., Cui, H., Liu, Y., Zhong, B., Shen, X., Li, X., Zhang, B., Chen, S., Zheng, W., Liu, J., Luo, F., & Luo, Z. (2024). Molecular characterization of Chinese patients with small bowel adenocarcinoma. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03441-4

Vancouver

Jin B, Lv B, Yan Z, Li W, Song H, Cui H, et al. Molecular characterization of Chinese patients with small bowel adenocarcinoma. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03441-4

BibTeX
@article{Jin2024,
  author = {Jin, Bryan and Lv, Bin and Yan, Zhengqing and Li, Wenshuai and Song, Huan and Cui, Haoshu and Liu, Yao and Zhong, Bin and Shen, Xin and Li, Xiao and Zhang, Bei and Chen, Shiqing and Zheng, Wanwei and Liu, Jie and Luo, Feifei and Luo, Zhongguang},
  title = {Molecular characterization of Chinese patients with small bowel adenocarcinoma},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03441-4}
}
Kostenlos starten →